These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

989 related items for PubMed ID: 15025842

  • 1. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B.
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [Abstract] [Full Text] [Related]

  • 2. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
    Keane WF, Lyle PA, Reduction of Endpoints in NIDDM with the Angiotensin II Receptor Antagonist Losartan study.
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S22-5. PubMed ID: 12612946
    [Abstract] [Full Text] [Related]

  • 3. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
    Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM, RENAAL Study Group.
    Arch Intern Med; 2003 Jul 14; 163(13):1555-65. PubMed ID: 12860578
    [Abstract] [Full Text] [Related]

  • 4. Losartan in diabetic nephropathy.
    Perico N, Ruggenenti P, Remuzzi G.
    Expert Rev Cardiovasc Ther; 2004 Jul 14; 2(4):473-83. PubMed ID: 15225108
    [Abstract] [Full Text] [Related]

  • 5. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
    Parving HH, Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S.
    Ugeskr Laeger; 2001 Oct 01; 163(40):5514-9. PubMed ID: 11601117
    [Abstract] [Full Text] [Related]

  • 6. [Risk and prevention of diabetic nephropathy].
    Ravera M, Re M, Deferrari G.
    G Ital Nefrol; 2007 Oct 01; 24 Suppl 38():13-9. PubMed ID: 17922442
    [Abstract] [Full Text] [Related]

  • 7. Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
    Egan B, Gleim G, Panish J.
    Curr Med Res Opin; 2004 Dec 01; 20(12):1909-17. PubMed ID: 15701209
    [Abstract] [Full Text] [Related]

  • 8. Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency.
    Pisoni R, Faraone R, Ruggenent P, Remuzzi G.
    J Nephrol; 2002 Dec 01; 15(4):428-30. PubMed ID: 12243375
    [Abstract] [Full Text] [Related]

  • 9. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
    Agha A, Bashir K, Anwar E.
    Nepal Med Coll J; 2007 Jun 01; 9(2):79-83. PubMed ID: 17899953
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
    Burgess ED, Carides GW, Gerth WC, Marentette MA, Chabot I, Canadian Hypertension Society.
    Can J Cardiol; 2004 May 01; 20(6):613-8. PubMed ID: 15152291
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The renoprotective effects of RAS inhibition: focus on prevention and treatment of chronic kidney disease.
    Weir MR.
    Postgrad Med; 2009 Jan 01; 121(1):96-103. PubMed ID: 19179817
    [Abstract] [Full Text] [Related]

  • 14. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep 01; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 15. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.
    Kidney Int; 2004 Jun 01; 65(6):2309-20. PubMed ID: 15149345
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes.
    Winkelmayer WC, Zhang Z, Shahinfar S, Cooper ME, Avorn J, Brenner BM.
    Diabetes Care; 2006 Oct 01; 29(10):2210-7. PubMed ID: 17003295
    [Abstract] [Full Text] [Related]

  • 17. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
    Zanella MT, Ribeiro AB.
    Clin Ther; 2002 Jul 01; 24(7):1019-34. PubMed ID: 12182249
    [Abstract] [Full Text] [Related]

  • 18. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
    Arredondo A, Burke TA, Carides GW, Lemus E, Querol J.
    Rev Invest Clin; 2005 Jul 01; 57(3):399-405. PubMed ID: 16187699
    [Abstract] [Full Text] [Related]

  • 19. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
    Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D.
    J Am Soc Nephrol; 2007 May 01; 18(5):1540-6. PubMed ID: 17409317
    [Abstract] [Full Text] [Related]

  • 20. [The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus].
    Ravera M, Deferrari L, Ratto E, Vettoretti S, Parodi D, Deferrari G.
    Ital Heart J Suppl; 2003 Mar 01; 4(3):210-6. PubMed ID: 12784755
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.